{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"64.12","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"ORR is defined as the percent of participants with best overall response of partial response (PR) or better. Response is determined per IMWG uniform criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.","id":"OG000","title":"EN Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to study completion date (up to approximately 50 months)","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percent of Participants"}